249736-18-3

Upstream product

• 39499-34-8 5-methyl-3-isoxazolyl chloride 
• 249736-12-7 (S)-2-tert-Butoxycarbonylamino-3-methyl-butyric acid (S)-1-allyloxycarbonyl-2-(4-fluoro-phenyl)-ethyl ester 
• 249736-11-6 (S)-3-(4-Fluoro-phenyl)-2-hydroxy-propionic acid allyl ester 
• 124980-97-8 (S)-methyl-2-hydroxy-3-(4-fluorophenyl)propionate 
• 1132-68-9 L-4-fluorophenylalanine 
• 13734-41-3 t-Boc-L-valine 

Downstream Products

• 249736-19-4 (E)-(S)-5-[(S)-1-(2,4-Dimethoxy-benzyl)-2-oxo-pyrrolidin-3-yl]-4-((S)-3-(4-fluoro-phenyl)-2-{(S)-3-methyl-2-[(5-methyl-isoxazole-3-carbonyl)-amino]-butyryloxy}-propionylamino)-pent-2-enoic acid ethyl ester 
• 394217-83-5 (S)-3-Methyl-2-[(5-methyl-isoxazole-3-carbonyl)-amino]-butyric acid (S)-1-carboxy-2-(4-fluoro-phenyl)-ethyl ester 

Relevant academic research and scientific papers

Design and synthesis of irreversible depsipeptidyl human rhinovirus 3C protease inhibitors

Novel tripeptidyl C-terminal Michael acceptors with an ester replacement of the P2-P3 amide bond were investigated as irreversible inhibitors of the human rhinovirus (HRV) 3C protease (3CP). When screened against HRV serotype-14 the best compound was shown to have very good 3CP inhibition (kobs/[I]=270,000 M-1 s-1) and potent in vitro antiviral activity (EC50=7.0 nM).